BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2495709)

  • 1. Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction.
    Gulba DC; Fischer K; Barthels M; Polensky U; Reil GH; Daniel WG; Welzel D; Lichtlen PR
    Am J Cardiol; 1989 May; 63(15):1025-31. PubMed ID: 2495709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
    Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
    Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter dose-finding trial for thrombolysis with urokinase preactivated pro-urokinase (TCL 598) in acute myocardial infarction. German Preactivated Pro-Urokinase Study Group.
    Gulba DC; Bode C; Sen S; Topp J; Fischer K; Wolf H; Hecker H
    Cathet Cardiovasc Diagn; 1992 Jul; 26(3):177-84. PubMed ID: 1617708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. Prourokinase Study Group.
    Weaver WD; Hartmann JR; Anderson JL; Reddy PS; Sobolski JC; Sasahara AA
    J Am Coll Cardiol; 1994 Nov; 24(5):1242-8. PubMed ID: 7930246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Incidence of residual thrombi following successful thrombolytic therapy in acute myocardial infarct and their significance for the rate of early re-occlusion. A report of a multicenter dose-finding study for thrombolytic therapy with urokinase preactivated natural prourokinase (TCL 598)].
    Gulba DC; Bode C; Topp J; Höpp HW; Westhoff-Bleck M; Rafflenbeul W; Lichtlen PR
    Z Kardiol; 1990 Apr; 79(4):279-85. PubMed ID: 2113330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. The Pro-Urokinase for Myocardial Infarction Study Group.
    Kirshenbaum JM; Bahr RD; Flaherty JT; Gurewich V; Levine HJ; Loscalzo J; Schumacher RR; Topol EJ; Wahr DW; Braunwald E
    Am J Cardiol; 1991 Dec; 68(17):1564-9. PubMed ID: 1746455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accelerated plasminogen activator dose regimens for coronary thrombolysis. The TAMI-7 Study Group.
    Wall TC; Califf RM; George BS; Ellis SG; Samaha JK; Kereiakes DJ; Worley SJ; Sigmon K; Topol EJ
    J Am Coll Cardiol; 1992 Mar; 19(3):482-9. PubMed ID: 1537998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of reteplase on hemostasis variables: analysis of fibrin specificity, relation to bleeding complications and coronary patency.
    Meierhenrich R; Carlsson J; Seifried E; Pfarr E; Smolarz A; Neuhaus KL; Tebbe U
    Int J Cardiol; 1998 Jun; 65(1):57-63. PubMed ID: 9699932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coronary reperfusion studies with pro-urokinase in acute myocardial infarction: evidence for synergism of low dose urokinase.
    Kasper W; Hohnloser SH; Engler H; Meinertz T; Wilkens J; Roth E; Lang K; Limbourg P; Just H
    J Am Coll Cardiol; 1990 Sep; 16(3):733-8. PubMed ID: 2117622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
    Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
    Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pro-urokinase for infarct therapy].
    Spiecker M; Meyer J
    Herz; 1994 Dec; 19(6):326-35. PubMed ID: 7843689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolysis with prourokinase versus urokinase: an in vitro comparison.
    Fox D; Ouriel K; Green RM; Stoughton J; Riggs P; Cimino C
    J Vasc Surg; 1996 Apr; 23(4):657-66. PubMed ID: 8627903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy.
    Gulba DC; Barthels M; Westhoff-Bleck M; Jost S; Rafflenbeul W; Daniel WG; Hecker H; Lichtlen PR
    Circulation; 1991 Mar; 83(3):937-44. PubMed ID: 1900225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
    Collen D; Van de Werf F
    Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
    Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
    Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial.
    Ouriel K; Kandarpa K; Schuerr DM; Hultquist M; Hodkinson G; Wallin B
    J Vasc Interv Radiol; 1999 Sep; 10(8):1083-91. PubMed ID: 10496712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.
    Diefenbach C; Erbel R; Pop T; Mathey D; Schofer J; Hamm C; Ostermann H; Schmitz-Hübner U; Bleifeld W; Meyer J
    Am J Cardiol; 1988 May; 61(13):966-70. PubMed ID: 2452563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical study on the thrombolytic effect with different doses of urokinase in acute myocardial infarction. The Collaborative Research Group on Thrombolysis.
    Chin Med J (Engl); 1997 Jan; 110(1):43-6. PubMed ID: 9594320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of prourokinase injection in patients with ST-elevation myocardial infarction: phase IV clinical trials of the prourokinase phase study.
    Zhao L; Zhao Z; Chen X; Li J; Liu J; Li G;
    Heart Vessels; 2018 May; 33(5):507-512. PubMed ID: 29209778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.